Celecoxib enhances the sensitivity of non-small-cell lung cancer cells to radiation-induced apoptosis through downregulation of the Akt/mTOR signaling pathway and COX-2 expression

Pan Zhang¹, Dan He², Erqun Song¹, Mingdong Jiang³*, Yang Song¹*

¹ Key Laboratory of Luminescence and Real-Time Analytical Chemistry, Ministry of Education, College of Pharmaceutical Sciences, Southwest University, Chongqing, P. R. China
² Department of Oncology, Nuclear Industry Hospital, Chengdu, Sichuan, P. R. China
³ Department of Radiation Oncology, The Ninth People’s Hospital of Chongqing, Chongqing, P. R. China

* These authors contributed equally to this work.

Citation: Zhang P, He D, Song E, Jiang M, Song Y (2019) Celecoxib enhances the sensitivity of non-small-cell lung cancer cells to radiation-induced apoptosis through downregulation of the Akt/mTOR signaling pathway and COX-2 expression. PLoS ONE 14(10): e0223760. https://doi.org/10.1371/journal.pone.0223760

Abstract

The current study aimed to identify the radiosensitizing effect of celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, in combination with radiotherapy in non-small-cell lung cancer (NSCLC) cells. The combination of celecoxib potentiated radiation-induced apoptosis; however, no changes in cell cycle distribution and number of phosphorylated histone H2AX foci were detected, indicating a DNA damage-independent mechanism. In an in vivo mouse model, the tumor size was significantly decreased in the group combining celecoxib with radiation compared with the radiation only group. Phosphorylation of protein kinase B (Akt) and mammalian target of rapamycin (mTOR), as well as expression of COX-2 were significantly downregulated in cells treated with the combination of celecoxib and radiation compared with the radiation only group. The result indicated that celecoxib exhibits radiosensitizing effects through COX-2 and Akt/mTOR-dependent mechanisms. Induction the Akt/mTOR signaling pathway promotes radioresistance in various cancers, including NSCLC. Therefore, the current study suggested the therapeutic potential of combination therapy of celecoxib and radiation in the prevention of radioresistance.

Introduction

Lung cancer, particularly non-small-cell lung cancer (NSCLC), is one of the most common cancers worldwide [1]. Radiotherapy is a promising treatment strategy for enhancing the survival time of patients and promoting quality of life [2]. However, the development of radioresistance and severe side effects on normal tissues frequently result in failure to apply radiotherapy. Therefore, it is critical to develop an improved strategy to overcome radioresistance in lung cancer.
An ideal radiosensitizer is expected to have low or absent toxicity to normal cells. However, most radiosensitizers used in clinic, including nitroimidazoles, fluorouracil, cisplatin and Taxol, do not match this criterion due to high toxicity to normal tissues. Therefore, various approaches have been explored to develop potent radiosensitizers to establish more suitable treatment strategies. Growing evidence indicates that inflammation serves an important role in modulating radiation responsiveness of cells [3]. Inflammation suppresses the effectiveness of radiotherapy [4] and substantially contributes to the development and progression of cancer [5]. The goal of novel therapeutic approaches is to disrupt proinflammatory cytokines and to stimulate receptors and signaling cascades. The aim of the current study was to develop a new strategy to increase sensitivity to radiation.

Nonsteroidal anti-inflammatory drugs (NSAIDs) are used worldwide for the treatment of pain, inflammation and fever. Cyclooxygenase-2 (COX-2) is an important rate-limiting enzyme in prostaglandin synthesis and interferes with angiogenesis and metastasis [6–8]. Previous studies have reported that the inhibition of COX-2 is beneficial for chemotherapy [8, 9]. Notably, COX-2 overexpression is frequently observed in human premalignant, malignant and metastatic epithelial tumors, including lung, breast, colorectal and prostate cancer [10, 11]. Suppression of COX-2 has been proposed to be associated with chemopreventive effects of NSAIDs. However, whether NSAIDs serve a role in the resistance of radiotherapy is currently unknown.

Celecoxib belongs to the NSAIDs family and is a potent and COX-2-specific inhibitor. NSAIDs are commonly linked to side effects, including bleeding and perforation in the gastrointestinal system in chronic NSAID users [12]. Celecoxib has been demonstrated to be less toxic compared with traditional NSAIDs [13]. Preclinical studies have revealed that COX-2 inhibitors lower the proliferation of human lung cancer cells in combination with chemotherapy [14]; however, whether the combination of COX-2 inhibitors with radiotherapy has a better effect in NSCLC has not been investigated in clinical trials or laboratory studies. A previous study suggested that anticancer effects of celecoxib are independent of COX-2 inhibition [15]. Later mechanistic studies indicated that celecoxib exhibits proapoptotic effects by inhibiting 3-phosphoinositide-dependent kinase-1 (PDK-1) and the downstream protein kinase B (Akt) signaling pathway in human colon cancer cells [16]. A recent study demonstrated that celecoxib downregulates specificity protein 1 by inhibiting c-Jun N-terminal kinase, thus enhancing the radiation sensitivity and inhibiting the migration and invasion of cancer cells [17]. To confirm this assumption, the current study evaluated effects of celecoxib on radiation response of NSCLC cells. In addition, possible underlying cellular mechanisms were investigated. The current study suggested the therapeutic potential of combination therapy of celecoxib and radiation in the prevention of radioresistance.

Materials and methods

Chemicals and reagents

Celecoxib was purchased from Dalian Meilun Biology Technology Co., Ltd. (Dalian, China), dissolved in dimethyl sulfoxide (DMSO; 10 mM) and diluted with ddH₂O immediately prior to each experiment. The final concentration of DMSO was <0.2%. Procedures of celecoxib preparation were previously described [18]. The Cell counting kit-8 (CCK-8) and the terminal transferase-mediated dUTP-biotin nick end labeling (TUNEL) assay kit were purchased from Beyotime Institute of Biotechnology (Nanjing, China). L-glutamine, penicillin and streptomycin were purchased from Aladdin Reagent Co., Ltd. (Shanghai, China). All antibodies details are reported in Table 1. All chemicals used were of the highest commercial grade.
Cell culture

NSCLC cell lines A549, H1299, L78 and PGCL3 were obtained from The Third Military Medical University (Chongqing, China). Cells were maintained in Dulbecco’s modified Eagle’s medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (Hangzhou Sijiqing Biological Engineering Materials Co., Ltd., Hangzhou, China), L-glutamine (2 mM), penicillin (100 U/ml) and streptomycin (100 μg/ml) at 37˚C with 5% CO₂ in an humidified incubator. Cell numbers were determined using a hemocytometer. Irradiation was performed using a cobalt-60 gamma-ray irradiator at 2–6 Gy/min.

Table 1. Antibody details.

| Protein       | Cat. no.   | Dilution | Supplier                    |
|---------------|------------|----------|-----------------------------|
| γ-H2AX        | D155226    | 1:300    | Sangon Biotech Co., Ltd.*   |
| p-Akt         | D151416    | 1:300    | Sangon Biotech Co., Ltd.*   |
| Akt           | D120056    | 1:300    | Sangon Biotech Co., Ltd.*   |
| p-mTOR        | D151417    | 1:300    | Sangon Biotech Co., Ltd.*   |
| mTOR          | D160640    | 1:300    | Sangon Biotech Co., Ltd.*   |
| β-actin       | D195301    | 1:300    | Sangon Biotech Co., Ltd.*   |
| Cyclin B1     | 55004-1-AP | 1:500    | ProteinTech Group, Inc.b    |
| COX-2         | 12375-1-AP | 1:500    | ProteinTech Group, Inc.b    |
| Parp1         | 13371-1-AP | 1:500    | ProteinTech Group, Inc.b    |
| caspase 3     | 19677-1-AP | 1:500    | ProteinTech Group, Inc.b    |
| Bcl-2         | 12789-1-AP | 1:500    | ProteinTech Group, Inc.b    |
| Alexa Fluor555| A-21428    | 1:250    | Invitrogenc                 |
| IgG-HRP       | D110117    | 1:1,000  | Sangon Biotech Co., Ltd.*   |

*Sangon Biotech Co., Ltd., Shanghai, China  
^ProteinTech Group, Inc. Chicago, IL, USA  
^Invitrogen; Thermo Fisher Scientific, Waltham, MA, USA.

γ-H2AX, phosphorylated histone H2AX; COX-2, cyclooxygenase-2; mTOR, mammalian target of rapamycin; Akt, protein kinase B; p-, phosphorylated; HRP, horseradish peroxidase.

https://doi.org/10.1371/journal.pone.0223760.t001

Cell viability assay

A549, H1299, L78 and PGCL3 cells were seeded in 96-well culture plates at 1x10⁴ cells/well. Cells were pretreated with 2 or 5 μM of celecoxib for 24 h and then irradiated at 2, 4 and 6 Gy/min for 1 min; The maximum dosage of 6 Gy was selected based on a previous publication [19]. Celecoxib concentrations were adapted from a previous publication [18]. Following radiation, cells were cultured for 24 h, medium was removed and replaced with CCK-8 solution and cells were incubated for further 4 h. A total of 10 μl kit reagent was added to each well and samples were incubated for another 3 h. The optical density (OD) value determined at 450 nm using a microplate reader.

Clonogenic survival assay

A549 cells (1x10⁵/well) were plated in collagen-coated 6-well plates and incubated overnight to adhere. Cells were pretreated with celecoxib (5 μM) for 24 h and then irradiated at 2 Gy/min for 1 min. Cells were cultured for 24 h and replaced with drug-free medium. The cells were then maintained at 37˚C for 14 days to allow for the formation of colonies, fixed in 4% paraformaldehyde for 5 min at room temperature, washed three times with PBS and stained with pure methylene blue [2 g/l in 1:1 (v/v) EtOH/H₂O] for 15 min. Colonies with >50 cells were
selected and counted under a microscope. Synergism graphs on colony reduction were constructed by Microsoft Excel 2016.

**Cell cycle arrest assay**

To distinguish cells in various cell cycle phases by flow cytometry, the DNA content was quantified using propidium iodide (PI). Following incubation of A549 cells (1x10^5/well) with celecoxib (5 μM) for 24 h, cells were irradiated at 2 Gy/min for 1 min, cultured for 24 h, harvested and washed twice with PBS. Cells were fixed overnight in 70% ethanol at 4˚C and stained with PI (5 μg/ml) for 30 min at 4˚C in the dark. Fluorescence of PI was recorded (excitation, 488 nm; emission, 530 nm) by flow cytometer. DNA content and cell cycles were analyzed using a flow cytometer and the percentage of cells in each phase was calculated by FlowJo 10.0.

**Apoptosis assay**

A549 cells (1x10^5/well) were preincubated with celecoxib (5 μM) for 24 h, irradiated at 2 Gy/min for 1 min, cultured for 24 h, harvested and washed with ice-cold PBS. Then, cells were trypsinized and resuspended in binding buffer (10 mM HEPES, pH 7.4, 140 mM NaCl, 1mM MgCl_2, 5mM KCl, 2.5 mM CaCl_2). Aliquots (100 μl) of cell solution were mixed with 5 μl Annexin V- fluorescein isothiocyanate (BD Biosciences, San Jose, CA, USA) and 10 μl PI (stock concentration, 50 μg/ml) and incubated in the dark for 2 h at room temperature. Binding buffer (400 μl) was added to each sample and cells were analyzed by a FACSscan flow cytometer. The percentage of apoptotic cells was calculated with >10,000 cells/sample and data analysis was performed using CellQuest 5.1 software (BD Biosciences).

**Immunocytochemistry for phosphorylated histone H2AX (γ-H2AX) foci detection**

Immunocytochemistry was performed to determine the nuclear distribution of γ-H2AX in radiated cells. Following preincubation of A549 cells (1x10^5/well) with celecoxib (5 μM) for 24 h and irradiation at 2 Gy/min for 1 min, cells were cultured for further 24 h. Cells were then fixed with 4% paraformaldehyde for 5 min at room temperature and permeabilized with 0.2% Triton X-100 for 10 min at room temperature in PBS. Following blocking with 10% nonfat milk for 30 min at room temperature, cells were incubated with primary antibody against γ-H2AX (dilution, 1:300) at 4˚C for 12 h. Then, cells were incubated with secondary antibody conjugated with Alexa Fluor555 for 1 h at 37˚C. Cells were incubated with DAPI (5 μg/ml) for 15 min at room temperature to confirm the distribution of foci. The morphology was observed by fluorescence microscopy (40x).

**TUNEL assay**

A549 cells (1x10^5/well) were pretreated with celecoxib (5 μM) for 24 h and irradiated at 2 Gy/min for 1 min. Following culturing for 24 h, cells were fixed in ice-cold 4% paraformaldehyde for 5 min at room temperature, washed with PBS and analyzed for apoptotic cells using a TUNEL assay kit following the manufacturer’s instructions.

**Animal experiments**

A total of 18 male BALB/c nude mice (age, 4–6 weeks; weight, 18–24 g) were used and the experimental protocols were approved by the Animal Care Committee of Southwest University (Chongqing, China) (#2017-M086) and were in accordance with the guidelines of National Institutes of Health guidelines. Several efforts were conducted to minimize animal suffering,
including socially housed together (<6) indoors in suspended stainless steel cages in a temperature-regulated room (~22˚C) with 12-h light/dark cycles, free access to water and standard mouse chow ad libitum. Tumor xenografts were established in nude mice that were injected with 1 x 10^7 A549 cells in the flank and tumors were allowed to develop. When the tumor volume reached 75 mm^3, mice were randomized into 3 groups (n = 6/group). Celecoxib (20 mg/kg body weight) was administered at the tumor site 1 h prior to irradiation; the dose was adjusted from a previous publication [20]. Mice in the irradiation and irradiation+celecoxib groups were irradiated with 10 Gy three times with a 7-days of interval. Tumor length and width were measured with a caliper every day and tumor volumes were calculated with the following formula: length (mm) x (width [mm])^2 x0.52. The standard protocol entailed euthanasia of mice by CO\textsubscript{2} inhalation, euthanasia was achieved by delivering 100% CO\textsubscript{2} for a minimum of 3 min from a pressurized system into an enclosed non-precharged cage containing the animal, followed by exsanguination. Tumors were removed and homogenated for further study.

**Western blotting analysis**

A549 cells were seeded in a dish (60 mm) at 1x10^6 cells/ml using 5 ml full medium and were cultured for 24 h to adhere. Following the pretreatment with celecoxib (5 μM) for 24 h and irradiation at 2 Gy/min for 1 min, cells were cultured for further 24 h. Cells were harvested, washed with ice cold PBS and lysed with radioimmunoprecipitation assay buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% SDS, 1% sodium deoxycholate and 1 mM phenylmethylsulfonyl fluoride) for 30 min on ice. For animal study, tumor tissues were homogenated. Proteins (80 μg) were resolved on 8 or 10% SDS-PAGE gels and transferred to nitrocellulose membranes. The blots were blocked with 5% dried skim milk dissolved in TBST (10 mM TBS plus 1.0% Tween 20) for 1.5 h at room temperature. Membranes were incubated with primary antibodies for 3 h at 37˚C followed by incubation with secondary goat anti-rabbit IgG-horseradish peroxidase-conjugated antibody for 2 h at 37˚C (Table 1). Antibody binding was detected using enhanced chemiluminescence reagents.

**Statistical analysis**

Data are presented as the mean ± standard deviation (n≥3). All data were analyzed using SPSS 19.0 (IBM Corp., Armonk, NY, USA). Statistical significance was determined using Student’s t-test or ANOVA. Tukey’s test was used in post hoc analysis for ANOVA. A probability value of p<0.05 or p<0.01 was considered to be statistically significant.

**Results**

**Celecoxib improves radiosensitivity of NSCLC cells**

First, the cytotoxicity effect of celecoxib was determined in A549 cell lines. As shown in Fig 1A, 5 μM of celecoxib showed no significant cytotoxicity. To determine whether celecoxib improved radiosensitivity, various NSCLC cell lines, including A549, H1299, L78 and PGCL3, were treated with celecoxib and exposed to varying doses of radiation (2–6 Gy) for 24 h. According to an existing reference, patients with locoregionally advanced nasopharyngeal carcinoma received a total radiation dose of 72–76 Gy in 36–38 fractions to the primary lesion and 60 Gy in 30 fractions to cervical lymph-node lesions and celecoxib was administered at escalating doses of 400, 600 and 800 mg/day [21]. Therefore, the current study established lower doses compared with clinical practice.

In the cell viability assays it was observed that radiation caused a dose-dependent reduction in cell survival in all cell lines (Fig 1B–1E). DMSO or celecoxib alone had no significant effect
on cell viability. Treatment with celecoxib (5 μM) for 24 h prior to radiation resulted in a significant decrease in cell viability compared with the celecoxib untreated but radiated samples. These findings indicated that celecoxib may induce a synergic effect of enhancing radiation efficacy. A549 cells exhibited a moderate effect against radiation challenge and were chosen for subsequent experiments. In Fig 2, data indicated that celecoxib treatment significantly reduced colony numbers of irradiated A549 cells compared with the radiation only group. Collectively, these results suggested that celecoxib enhanced the radiation sensitivity of NSCLC cells and current finding are consistent with previous publications [19, 22, 23].

**Celecoxib enhances radiation-induced apoptosis**

To investigate the induction of apoptosis following radiation, with or without celecoxib treatment, early apoptosis was determined by Annexin V/PI double staining. The percentage of early apoptotic cells significantly increased following radiation (2 Gy) compared with the untreated control (Fig 3A). Celecoxib treatment of radiated cells further significantly increased the radiation-induced apoptosis levels. Apoptotic effects of celecoxib and radiation in combination were evaluated using TUNEL assays. In accordance with the flow cytometry results,
radiation significantly induced cell death compared with the untreated control and celecoxib treatment of radiated cells further significantly increased the numbers compared with the radiation group (Fig 3B). These results were confirmed by an assessment of apoptosis-related proteins. Western blotting result showed Parp1 cleavage, caspases 3 activation on treatment with Celecoxib in combination with radiation, in comparison to that observed in the groups treated with radiation alone. On the contrary, the expressions of anti-apoptotic Bcl-2 protein were clearly decreased in both groups and Celecoxib plus radiation group showed a greater extent than radiation treatment alone (Fig 3C).

Celecoxib has no effect on DNA damage and cell cycle distribution in radiated NSCLC cells

To investigate what cellular mechanisms may enhance radiation-induced cell death following celecoxib treatment of radiated cells, effects of celecoxib on DNA damage and cell cycle populations were examined. As presented in Fig 4A, the number of γ-H2AX-positive foci was significantly enhanced by radiation compared with the untreated control. The combination of celecoxib with radiation resulted in a minimal increase and no significance was observed compared with the radiation only group. Other data indicated that radiation significantly altered the phase distribution of A549 cells compared with the untreated control (Fig 4B), with redistribution from the G0/G1 to the G2/M phases. The combination of celecoxib and radiation exhibited no significant changes compared with the radiation only group. Expression of cell cycle regulator cyclin B1 was assessed by western blot. As presented in Fig 4C, no significant
changes in cyclin B1 expression were observed between the untreated, the radiation only and the combination groups.

**Celecoxib reverses radiation-induced effects on the AKT/mammalian target of rapamycin (mTOR) signaling pathway and COX-2 protein expression**

As demonstrated in Fig 5, celecoxib treatment reduced radiation-induced phosphorylation of Akt and mTOR compared with the radiation only group. Celecoxib further attenuated COX-2

Fig 3. The effect of celecoxib and radiation on apoptosis. A549 cells were exposed to combination of celecoxib and radiation for 24 h. (A) Cells were stained for Annexin V and PI staining and analyzed using flow cytometry, and the number of apoptotic population was presented. (B) Cells were fixed and analyzed for apoptotic cell death by TUNEL assay. Data were shown as the mean ± SD of three different experiments. **P<0.001 indicated significant difference between control and radiation alone group, ***P<0.001 indicated significant difference between radiation alone with radiation plus Celecoxib groups. (C) Western blotting analysis of apoptosis-related protein expressions. β-Actin was used as loading control.

https://doi.org/10.1371/journal.pone.0223760.g003
expression, which was elevated following radiation. These findings indicated that the mechanism of the radiosensitizing effect of celecoxib in A549 cells may be associated with the inhibition of radiation-induced activation of the AKT/mTOR signaling pathway and COX-2 expression.

**Celecoxib enhances tumor growth inhibition in a A549 radiated mouse model**

To confirm the radiosensitizing effect of celecoxib in vivo, a mouse model was established. Tumor volumes were significantly decreased in the radiosensitized mice compared with the untreated control at the endpoint of experiment (at day 20) (Fig 6). On day 10, the tumor volume was ~3-times higher in control mice compared with mice that received irradiation. The combination of radiation and celecoxib treatment decreased tumor volumes compared with the radiation only group (decreased by 22 and 35% on days 10 and 20, respectively).

**Fig 4. The effect of celecoxib and radiation on the formation of γ-H2AX foci and cell cycle distribution.** (A) A549 cells were treated with or without 5 μM Celecoxib followed by radiation of 2 Gy for 24 h. Cells were fixed and labeled with anti-γ-H2AX primary antibody and Alexa Fluor 555 conjugated secondary antibody. γ-H2AX foci were observed by fluorescence microscopy. Nuclei were counterstained with DAPI. The number of γ-H2AX foci per cell was counted at least 50 cells for each condition. The average number was expressed as the mean ± SD of three different experiments. *P<0.001 indicated significant difference between control and radiation alone group. NS, no significance. (B) Cell cycle distribution in A549 cells with radiation treatment in combination with or without Celecoxib, and then analyzed by the flow cytometer. (C) Western blotting analysis of Cyclin B1 protein. β-Actin was used as loading control. Data are presented as the mean ± standard deviation, n = 3. ***P<0.001 vs. control. γ-H2AX, phosphorylated histone H2AX.

https://doi.org/10.1371/journal.pone.0223760.g004
tumor diameter for a single subcutaneous tumor was 1.75, 1.40 and 1.05 cm for the control, radiation only and combination treatment groups, respectively. We further investigated the Akt/mTOR signaling and COX-2 expression in tumors, as shown, similar results were obtained compare with in vitro experiments (Fig 7). The results suggested synergistic effects of the combination treatment.

**Discussion**

Increasing the radiotherapy dose alone is not sufficient to increase the overall survival rate of cancerous patients. Therefore, there is an urgency to develop novel strategies to benefit the patients. For instance, the combination of radiosensitizers is a promising route. In the current study, it was revealed that NSCLC cell lines were affected by the co-treatment of celecoxib and radiation.

COX-2 inhibitors, including celecoxib, induce apoptosis at higher concentrations in NSCLC cell lines [24, 25] suggesting potential clinical applications for the combination of celecoxib with radio- and chemotherapy in NSCLC treatment [26]. However, trials reported contradictory results. A recent meta-analysis indicated that celecoxib induces adverse effects based on its therapeutic regimens or dosage [27]. The COX-2 inhibitor neither exaggerated nor antagonized the proapoptotic activity of chemotherapeutic agents in NSCLC cells [14, 28]. In addition, while certain reports support beneficial effects of combination treatment of celecoxib
with radio- and chemotherapy, severe hematological toxicity cannot be omitted. A majority of clinical trials combined COX-2 inhibitors with chemotherapy rather than radiotherapy.

The role of celecoxib in cancer treatment has been extensively reviewed. The proapoptotic effect of celecoxib in Friend’s leukemia cancer cells has been attributed to COX-2 inhibition and subsequently restricts prostaglandin-mediated antiapoptotic protein expression [29]. Celecoxib regulates cell survival - and cell death-associated genes, including PDK-1, Akt, survivin, B-cell lymphoma 2 and myeloid leukemia cell differentiation protein 1 [30, 31]. Additionally to the role of celecoxib in COX-2 inhibition, mechanisms of proapoptotic effects of celecoxib have been reported. Individual studies have suggested that extrinsic and intrinsic apoptotic
pathways are induced by celecoxib and associated compounds [32, 33]. The activation of the endoplasmic reticulum stress response is an early event for celecoxib-induced apoptosis [34]. Irradiation and antineoplastic drugs damage DNA; however, celecoxib-induced apoptosis is different and a putative benefit for the combination of celecoxib with radio- or chemotherapy has been suggested. Due to its selective interaction with COX-2, celecoxib is expected to pose less risk for gastrointestinal side effects and toxic effects of celecoxib have been attributed to the inhibitory action on COX-2. Therefore, the development of celecoxib derivatives without COX-2-inhibitory action describe a promising strategy for the treatment of COX-2-negative tumors [35]. It remains to be defined whether celecoxib and its derivatives may target apoptosis-associated genes.

In summary, the present study demonstrated that celecoxib exerted a radiosensitizing effect in radiated NSCLC cells by regulating the apoptosis-associated Akt/mTOR signaling pathway. The dosage of celecoxib used in the in vivo experiments combined with radiotherapy was decreased compared with current clinical standards and may have potential beneficial implications for patients with lung cancer.

**Author Contributions**

**Conceptualization:** Pan Zhang, Erqun Song, Mingdong Jiang, Yang Song.

**Data curation:** Pan Zhang, Dan He, Yang Song.
Formal analysis: Pan Zhang, Dan He.
Funding acquisition: Mingdong Jiang.
Investigation: Dan He.
Methodology: Dan He.
Project administration: Mingdong Jiang, Yang Song.
Software: Dan He, Erqun Song.
Supervision: Yang Song.
Validation: Erqun Song.
Writing – original draft: Pan Zhang.
Writing – review & editing: Erqun Song, Mingdong Jiang, Yang Song.

References
1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017; 67(1):7–30. https://doi.org/10.3322/caac.21387 PMID: 28055103.
2. Eberhardt WE. Concurrent chemoradiotherapy in stage III non-small-cell lung cancer: what is the best regimen? J Clin Oncol. 2015; 33(6):532–3. https://doi.org/10.1200/JCO.2014.58.9812 PMID: 25559800.
3. Multhoff G, Radons J. Radiation, inflammation, and immune responses in cancer. Front Oncol. 2012; 2:58. https://doi.org/10.3389/fonc.2012.00058 PMID: 22675673; PubMed Central PMCID: PMC3366472.
4. Molla M, Panes J. Radiation-induced intestinal inflammation. World J Gastroenterol. 2007; 13(22):3043–6. https://doi.org/10.3745/wjg.v13.i22.3043 PMID: 17599118; PubMed Central PMCID: PMC4172609.
5. Cossens LM, Werb Z. Inflammation and cancer. Nature. 2002; 420(6917):860–7. https://doi.org/10.1038/nature01322 PMID: 12490959; PubMed Central PMCID: PMC2803035.
6. Cheki M, Yahyapour R, Farhood B, Rezaeeyan A, Shabeel D, Amini P, et al. COX-2 in Radiotherapy: A Potential Target for Radioprotection and Radiosensitization. Curr Mol Pharmacol. 2018; 11(3):173–83. Epub 2018/02/23. https://doi.org/10.2174/1874467211666180219102520 PMID: 29468988.
7. DuBois RN, Tsuji M, Bishop P, Awad JA, Makata K, Lanahan A. Cloning and characterization of a growth factor-inducible cyclooxygenase gene from rat intestinal epithelial cells. Am J Physiol. 1994; 266(5 Pt 1):G822–7. https://doi.org/10.1152/ajpgi.1994.266.5.G822 PMID: 8203528.
8. Han ZQ, Liao H, Shi F, Chen XP, Hu HC, Tian MQ, et al. Inhibition of cyclooxygenase-2 sensitizes lung cancer cells to radiation-induced apoptosis. Oncol Lett. 2017; 14(5):5959–65. https://doi.org/10.3892/ol.2017.6940 PMID: 29113232; PubMed Central PMCID: PMC5661612.
9. Cho SJ, Kim N, Kim JS, Jung HC, Song JS. The anti-cancer effect of COX-2 inhibitors on gastric cancer cells. Dig Dis Sci. 2007; 52(7):1713–21. https://doi.org/10.1007/s10620-007-9787-3 PMID: 17393325.
10. Brown JR, DuBois RN. COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol. 2005; 23(12):2840–55. https://doi.org/10.1200/JCO.2005.09.051 PMID: 15837998.
11. Sung JJ, Leung WK, Go MY, To KF, Cheng AS, Ng EK, et al. Cyclooxygenase-2 expression in Helicobacter pylori-associated premalignant and malignant gastric lesions. Am J Pathol. 2000; 157(3):729–35. https://doi.org/10.1016/S0002-9440(10)64586-5 PMID: 10980112; PubMed Central PMCID: PMC1885697.
12. Kismet K, Akay MT, Abbasoglu O, Ercan A. Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention. Cancer Detect Prev. 2004; 28(2):127–42. https://doi.org/10.1016/j.cdp.2003.12.005 PMID: 15068837.
13. Needleman P, Isakson PC. The discovery and function of COX-2. J Rheumatol Suppl. 1997; 49:6–8. PMID: 9249644.
14. Hida T, Kozaki K, Ito H, Miyaiishi O, Tatematsu Y, Suzuki T, et al. Significant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase-2 inhibitor, JTE-522, and conventional anticancer agents. Clin Cancer Res. 2002; 8(7):2443–7. PMID: 12114451.
Celecoxib enhances the radiosensitivity of HCT116 cells in a COX-2-dependent manner by up-regulating BCCIP. Cancer Res. 2011; 66(14):7059–66. https://doi.org/10.1158/0008-5472.CAN-06-0325 PMID: 16849551.

15. Elder DJ, Halton DE, Hague A, Paraskeva C. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression. Clin Cancer Res. 1997; 3(10):1679–83. PMID: 9185550.

16. Arico S, Pattingre S, Bauvy C, Gane P, Barbat A, Codogno P, et al. Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J Biol Chem. 2002; 277(31):27613–21. https://doi.org/10.1074/jbc.M201119200 PMID: 12000750.

17. Liu R, Tan Q, Luo Q. Decreased expression level and DNA-binding activity of specificity protein 1 via cyclooxygenase-2 inhibition antagonizes radiation resistance, cell migration and invasion in radiation-resistant lung cancer cells. Oncol Lett. 2018; 16(3):3029–37. Epub 2018/08/22. https://doi.org/10.3892/os.2018.9035 PMID: 30127983; PubMed Central PMCID: PMC6096147.

18. Xu XT, Hu WT, Zhou JY, Tu Y. Celecoxib enhances the radiosensitivity of HCT116 cells in a COX-2-dependent manner by up-regulating BCCIP. Am J Transl Res. 2017; 9(3):1088–100. Epub 2017/04/08. PMID: 28386336; PubMed Central PMCID: PMC5376001.

19. Huang J, Yuan X, Pang Q, Zhang H, Yu J, Yang B, et al. Radiosensitivity enhancement by combined treatment of nimotuzumab and celecoxib on nasopharyngeal carcinoma cells. Drug Des Devel Ther. 2018; 12:2223–31. Epub 2018/07/25. https://doi.org/10.2147/DDDT.S163595 PMID: 30038488; PubMed Central PMCID: PMC6052925.

20. Kang KB, Wang TT, Woon CT, Cheah ES, Moore XL, Zhu C, et al. Enhancement of glioblastoma radioresponse by a selective COX-2 inhibitor celecoxib: inhibition of tumor angiogenesis with extensive tumor necrosis. Int J Radiat Oncol Biol Phys. 2007; 67(3):888–96. Epub 2007/02/13. https://doi.org/10.1016/j.ijrobp.2006.09.055 PMID: 17293239.

21. Xue WP, Bai SM, Luo M, Bi ZF, Liu YM, Wu SK. Phase I clinical trial of nasopharyngeal radiotherapy and concurrent celecoxib for patients with locoregionally advanced nasopharyngeal carcinoma. Oral Oncol. 2011; 47(8):755–7. https://doi.org/10.1016/j.oraloncology.2011.06.002 PMID: 21708478.

22. Sun J, Liu NB, Zhuang HQ, Zhao LJ, Yuan ZY, Wang P. Celecoxib-erlotinib combination treatment enhances radiosensitivity in A549 human lung cancer cell. Cancer Biomark. 2017; 19(1):45–50. Epub 2017/03/12. https://doi.org/10.3233/CBM-160323 PMID: 28282799.

23. Zhang SX, Qiu OH, Chen WB, Liang CH, Huang B. Celecoxib enhances radiosensitivity via induction of G2/M phase arrest and apoptosis in nasopharyngeal carcinoma. Cell Physiol Biochem. 2014; 33(5):1484–97. Epub 2014/05/24. https://doi.org/10.1159/000358713 PMID: 24854838.

24. Kim B, Kim J, Kim YS. Celecoxib induces cell death on non-small cell lung cancer cells through endoplasmic reticulum stress. Anat Cell Biol. 2017; 50(4):293–300. Epub 2018/01/23. https://doi.org/10.5115/acb.2017.50.4.293 PMID: 29354301; PubMed Central PMCID: PMC5768566.

25. Jendrossek V. Targeting apoptosis pathways by Celecoxib in cancer. Cancer Lett. 2013; 332(2):313–24. Epub 2011/02/25. https://doi.org/10.1016/j.canlet.2011.01.012 PMID: 21345576.

26. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 2000; 60(5):1306–11. PMID: 10728691.

27. Hou LC, Huang F, Xu HB. Does celecoxib improve the efficacy of chemotherapy for advanced non-small cell lung cancer? Br J Clin Pharmacol. 2016; 81(1):23–32. https://doi.org/10.1111/bcp.12757 PMID: 26331772; PubMed Central PMCID: PMC4693572.

28. Chen M, Yu L, Gu C, Zhong D, Wu S, Liu S. Celecoxib antagonizes the cytotoxic effect of cisplatin in human gastric cancer cells by decreasing intracellular cisplatin accumulation. Cancer Lett. 2013; 329(2):189–96. https://doi.org/10.1016/j.canlet.2012.09.030 PMID: 23142285.

29. Cataldi A, Zauli G, Di Pietro R, Castorina S, Rana R. Involvement of the pathway phosphatidylinositol-3-kinase/Akt/AKT-1 in the establishment of the survival response to ionizing radiation. Cell Signal. 2001; 13(5):369–75. https://doi.org/10.1016/s0898-6568(01)00147-4 PMID: 11369519.

30. Rudner J, Elsaesser SJ, Muller AC, Belka C, Jendrossek V. Differential effects of anti-apoptotic Bcl-2 family members Mcl-1, Bcl-2, and Bcl-xL on celecoxib-induced apoptosis. Biochem Pharmacol. 2010; 79(1):10–20. https://doi.org/10.1016/j.bcp.2009.07.021 PMID: 19665451.

31. Wu T, Leng J, Han C, Demetris AJ. The cyclooxygenase-2 inhibitor celecoxib blocks phosphorylation of Akt and induces apoptosis in human cholangiocarcinoma cells. Mol Cancer Ther. 2004; 3(3):299–307. PMID: 15026550.

32. Belka C, Rudner J, Wesselborg S, Stepczynska A, Marini P, Lepple-Wienhues A, et al. Differential role of caspase-8 and BID activation during radiation- and CD95-induced apoptosis. Oncogene. 2000; 19(9):1181–90. https://doi.org/10.1038/sj.onc.1203401 PMID: 10715706.

33. Kern MA, Haugg AM, Koch AF, Schilling T, Breuhahn K, Walczak H, et al. Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma. Cancer Res. 2006; 66(14):7059–66. https://doi.org/10.1158/0008-5472.CAN-06-0325 PMID: 16849551.
34. Alloza I, Baxter A, Chen Q, Matthiesen R, Vandenbroeck K. Celecoxib inhibits interleukin-12 alphabeta and beta2 folding and secretion by a novel COX2-independent mechanism involving chaperones of the endoplasmic reticulum. Mol Pharmacol. 2006; 69(5):1579–87. https://doi.org/10.1124/mol.105.020669 PMID: 16467190.

35. Schonthal AH. Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy. Br J Cancer. 2007; 97(11):1465–8. https://doi.org/10.1038/sj.bjc.6604049 PMID: 17955049; PubMed Central PMCID: PMC2360267.